Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Gilead Sciences has completed the acquisition of YM BioSciences.
Subscribe to our email newsletter
A Gilead subsidiary acquired all YM’s outstanding common shares as per the terms of a plan of arrangement.
Thus, YM has become a wholly-owned subsidiary of Gilead.
YM shareholders will be entitled to receive $2.95 per common share in cash, and holders of warrants and stock options will be eligible for a cash payment equal to the difference between $2.95 and the exercise price of such warrant or stock option.